Predict your next investment

Private Equity
utc.co.kr

See what CB Insights has to offer

Investments

56

Portfolio Exits

3

Funds

24

About UTC Investment

UTC Investment is a private equity & venture capital firm based in South Korea. UTC Investment implements and develops private equity investments with deep roots in the buyout area, diversified human resources, and impressive track records.

UTC Investment Headquarter Location

2F, Taeyoung Building 111, Yeouigongwon-ro, Yeongdeungpo-gu

Seoul, 07241,

South Korea

+82 2-783-3347

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest UTC Investment News

Healthcare service provider NGeneBio Co., Ltd. receives $10 million from multiple investors

Mar 11, 2021

Healthcare service provider NGeneBio Co., Ltd. receives $10 million from multiple investors NGeneBio Co., Ltd. a leading company in molecular diagnostics (MDx) and companion diagnostics (CDx), recently received 12 billion won or $ 10 million worth of investment from multiple venture capitals like UTC Investment, IMM Investment, DSC Investment and SL Investment. NGeneBio, which was founded in October 2015, is headquartered in Seoul and is a joint venture between Genecurix and Korea Telecom. Innovator in Precision Medicine NGeneBio is known for its innovative products and services based on competencies in bioinformatics and expertise in molecular diagnostics (MDx). The startup’s focus is to develop various MDx and companion diagnostics (CDx) products which predict efficacy and safety of targeting therapeutics. The company also develops and provides next-generation sequencing (NGS)-based in vitro diagnostics (IVD) panel and clinical analysis software (SW). “NGeneBio’s product & services are convenient for both of physicians and patients.” The company also launched an NGS-based hereditary breast/ovarian cancer panel (BRCAaccuTestTM) with clinical analysis S/W (NGeneAnalysisTM) and received their CE-IVD mark in June 2017. In the near future, the startup wants to launch NGS panels for a solid tumour/hematologic malignancies and BRCA PARP inhibitor CDx test, inclusive of clinical data analysis SW platform. Mission to become leading global healthcare service provider NGeneBio’s mission is to work with the support of the laboratory medicine community to provide clinically validated NGS-IVD / CDx products/services with the convergence of innovative biotechnology and bioinformatics. The company is already working on research and development projects in cooperation with an anticancer diagnosis project team, domestic and foreign hospitals and biotech companies. The firm is striving to secure technology and develop a business model of mid- to long-term perspectives through external patent license-in, in addition to the company’s own patent discovery. The latest investment has certainly boosted the chances of further developments in the field of molecular diagnostics (MDx) and companion diagnostics (CDx) for the company. “We will grow into a global healthcare company leading the precision medical market in the era of the Fourth Industrial Revolution by focusing on high-quality service development, technological advancement and global market expansion through investment attraction,” said Daechul Choi, the CEO of NGeneBio. The company’s goal is to be a global healthcare service provider based on four core values ​​of challenging execution, respect for life, human resource development and customer trust. What’s your thoughts?

UTC Investment Investments

56 Investments

UTC Investment has made 56 investments. Their latest investment was in ImmuneMed as part of their Series D on November 11, 2021.

CBI Logo

UTC Investment Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/3/2021

Series D

ImmuneMed

$10.16M

No

1

8/30/2021

Series C

TiCARos

$21.48M

Yes

1

8/6/2021

Series C

NORMA

$9.6M

Yes

2

7/21/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

7/14/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/3/2021

8/30/2021

8/6/2021

7/21/2021

7/14/2021

Round

Series D

Series C

Series C

Series A

Series A

Company

ImmuneMed

TiCARos

NORMA

Subscribe to see more

Subscribe to see more

Amount

$10.16M

$21.48M

$9.6M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

2

10

10

UTC Investment Portfolio Exits

3 Portfolio Exits

UTC Investment has 3 portfolio exits. Their latest portfolio exit was NGeneBio on December 10, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/10/2020

IPO

1

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

12/10/2020

00/00/0000

00/00/0000

Exit

IPO

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

10

10

UTC Investment Fund History

24 Fund Histories

UTC Investment has 24 funds, including United Turnaround 1st Recovery PEF.

Closing Date

Fund

Fund Type

Status

Amount

Sources

3/31/2011

United Turnaround 1st Recovery PEF

Early-Stage Venture Capital

1

8/31/2010

KoFC-UTC Pioneer Champ 2010-19th Fund

Early-Stage Venture Capital

1

7/2/2010

UTC 1st Korea Venture Fund

Early-Stage Venture Capital

$16.28M

1

6/9/2009

UTC 12th Venture Fund

Subscribe to see more

$99M

10

4/30/2009

UTC CRC 8th Fund

Subscribe to see more

$99M

10

Closing Date

3/31/2011

8/31/2010

7/2/2010

6/9/2009

4/30/2009

Fund

United Turnaround 1st Recovery PEF

KoFC-UTC Pioneer Champ 2010-19th Fund

UTC 1st Korea Venture Fund

UTC 12th Venture Fund

UTC CRC 8th Fund

Fund Type

Early-Stage Venture Capital

Early-Stage Venture Capital

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Amount

$16.28M

$99M

$99M

Sources

1

1

1

10

10

UTC Investment Team

3 Team Members

UTC Investment has 3 team members, including current Chief Executive Officer, Hoon Sik Kim.

Name

Work History

Title

Status

Hoon Sik Kim

Chief Executive Officer

Current

Jong Hyun Sung

Chief Executive Officer

Current

Yong Cheol Yong

Chief Executive Officer

Current

Name

Hoon Sik Kim

Jong Hyun Sung

Yong Cheol Yong

Work History

Title

Chief Executive Officer

Chief Executive Officer

Chief Executive Officer

Status

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.